H-4-II-E大鼠肝细胞瘤（_普通细胞-上海富雨生物科技有限公司

H-4-II-E大鼠肝细胞瘤（返回列表页

参考价

面议

具体成交价以合同协议为准

产品型号

品牌

厂商性质生产商

所在地

在线询价加入对比查看联系电话

更新时间：2025-02-11 18:10:19浏览次数：37次

联系我时，请告知来自化工仪器网

大鼠肝细胞瘤H-4-II-E

种属	大鼠
别称	H-4-II-E; H4IIE
组织来源	肝脏
疾病	肝癌
传代比例/细胞消化	1:2传代,消化2-3分钟
培养基配置	MEM养基；10%胎牛血清；1%双抗
简介	H-4- Ⅱ-E细胞可诱导产生芳香烃羟化酶，用于检测环境样品或食物提取物种皮克级的有机化合物。
形态	上皮细胞样
生长特征	贴壁生长
倍增时间	每周 2 至 3 次
培养条件	气相：空气，95%；二氧化碳，5%。温度：37摄氏度，培养箱湿度为70%-80%。
冻存条件	冻存液：90%FBS ，DMSO 10%, 或使用非程序冻存液：货号JY-H040
保藏机构	ATCC; CRL-1548
产品使用	于科学研究，不可作为动物或人类疾病的治疗产品使用。

Introduction: Blunt traumatic aortic injury (TAI) is a critical condition and a leading cause of mortality in trauma patients, often resulting from high-speed accidents. Thoracic endovascular aortic repair (TEVAR) has developed into the preferred therapeutic approach due to its minimally invasive nature and promising outcomes. This study evaluates the safety and efficacy of TEVAR for managing TAI over a 10-year period at a Level-1 trauma center.

Methods: A retrospective analysis was conducted on 19 patients with acute TAI treated with TEVAR between 2012 and 2022 at the University Hospital Zurich. Data were collected from digital records and analyzed according to the Fillinger TEVAR reporting framework. Outcomes included technical success, perioperative complications, and long-term graft durability.